Why Partner with Us

Robust global networks

A truly global company, connecting over 30 countries

Multiple areas of opportunity

From co-developing drugs to out-licensing – collaboration is key

Legacy of results and delivery

Over 25 years of forwarding science at Dr. Reddy’s Biologics

Our Network of Partners

  • All
  • In-licensing
  • Out-licensing
  • Co-development
Alvotech
Healthcare Pharmaceuticals Limited
Coya Therapeutics

Processes Involved Toward Partnership

Please expect to go through the following processes on the way to successful deal closure. 

Write to us using the Enquiry Form below.

Non-Disclosure Agreement (NDA):
Business Case and Opportunity Assessment:
Term Sheet:
Due Diligence:
Licensing Agreement:
Supporting Agreements:
0/40
0/40
0/250

Our Network

Our News, Stories, and Insights

  • Publication
  • 09-10-2013

A Randomized, Multi Centre, Open-Label Study to Evaluate the Efficacy and Safety of Peg G-CSF as Compared to Grafeel in the Prophylaxis of Severe Neutropenia in Cancer Patients Receiving Cytotoxic Chemotherapy

  • Publication
  • 31-03-2025

Abstract No: 0556, ISNCON Conference 2014 A Randomized, Comparative, Open-label Clinical Trial of Darbepoetin Alfa Biosimilar for the Treatment of Anaemia in Pre-Dialysis Chronic Kidney Disease Patients

  • Publication
  • 23-04-2025

Abstract No: 0556, ISNCON Conference 2014 Efficacy and Safety of Indigenously Developed Darbepoetin Alfa in Dialysis Patients - A Randomised Study

  • News
  • 07-06-2025

Alvotech and Dr. Reddy’s to co-develop biosimilar candidate to Keytruda® (pembrolizumab)

Bricks of Biologics, appreciates the contribution and celebrates our people who are the building blocks of Dr. Reddy's Biologics.

 

Bricks of biologics in general refers to bio-bricks as genetic building blocks which are DNA sequences that can be assembled to create complex biological systems.